



EIKO LIFESCIENCES LIMITED

F E E L T H E C H E M I S T R Y

Date: 31st October, 2025

To,
Corporate Services Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
1st Floor, Dalal Street,
Fort, Mumbai - 400001.

Scrip Code: 540204

Subject: Outcome of the Board Meeting

Dear Sir/Madam,

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), and amendments thereto, this is to inform that the Meeting of the Board of Directors of the Company held today i.e., on Friday, 31st October, 2025, Board, inter-alia, considered and approved Un-Audited Financial Results (Standalone & Consolidated basis) for the Quarter and Half Year ended 30th September, 2025.

The Statutory Auditors have carried out a "Limited Review" of the Unaudited Financial Results for the Quarter and Half year ended 30th September, 2025. Further, Pursuant to the Regulation 33 of the Listing Regulations, we are enclosing herewith a copy of the Unaudited Financial Results and Limited Review Report of the Statutory Auditors of the Company.

The said results shall be published in Marathi and English newspaper as required. This intimation is also available on the Company's website at www.eikolifesciences.com.

The Meeting was commenced at 04: 45 PM and concluded at 5:30 PM.

Please take the same on your records.

For Eiko Lifesciences Limited

Chintan Doshi
Company Secretary and Compliance Officer
Membership No: A 36190



P S V JAIN & ASSOCIATES

Office No. 105, Shree Yaswant shopping Centre, Kasturba Rd., No. 7,
Borivali (E), Mumbai - 400066. Tel. : +91-22-28059888 Mob.: 9920689888
E-mail : psvjain.associates@gmail.com

Independent Auditor's Review Report on Standalone Unaudited Financial Results for Quarter and Half Year ended 30th September 2025 of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors
Eiko Lifesciences Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of **Eiko LifeSciences Limited** (The Company') for the quarter and half year ended 30th September 2025 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PSV JAIN & ASSOCIATES
Chartered Accountants
Firm Registration No.: 131505W

CA Vijay Kumar Jain
Partner

Membership No.: 405129



Place: Thane

Date: 31st October 2025

UDIN: 25405129BMUJYU6403



EIKO LIFESCIENCES LIMITED
(CIN: L65993MH1977PLC258134)

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2025

(INR in lakhs)

Sr. No.	Particulars	Quarter ended			Half Year Ended		Year ended
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	919.74	745.23	773.92	1,664.97	1,848.95	3,249.18
	Other income	56.47	55.37	13.07	111.85	39.29	102.40
	Total revenue	976.21	800.60	786.98	1,776.81	1,888.25	3,351.58
2	Expenses						
	Cost of material consumed	862.70	460.05	661.36	1,322.75	1,653.53	2,982.80
	Changes in inventories of finished stock and work-in-progress	(56.23)	196.38	34.10	140.15	33.94	(62.22)
	Employee benefits expense	7.03	5.85	5.91	12.88	11.22	28.29
	Depreciation and amortization expense	14.76	14.75	16.31	29.51	32.83	62.94
	Finance Cost	6.97	1.82	3.58	8.79	6.46	12.70
	Other expenses	34.18	30.97	37.71	65.15	76.12	129.39
	Total expenses	869.41	709.82	758.96	1,579.23	1,814.09	3,153.88
3	Profit/(Loss) from ordinary activities before Exceptional Items	106.80	90.77	28.03	197.58	74.15	197.69
	Exceptional Items	-	-	-	-	-	34.12
4	Profit/(Loss) from ordinary activities before Tax	106.80	90.77	28.03	197.58	74.15	231.82
5	Tax expense:						
	(1) Current tax	22.84	19.93	4.58	42.77	13.14	45.42
	(2) Deferred tax	2.21	1.62	2.64	3.83	5.52	12.32
6	Profit/(Loss) from ordinary activities after tax	81.76	69.22	20.81	150.98	55.49	174.08
7	Other Comprehensive Income (OCI)						
	Total Other Comprehensive Income (OCI)	-	-	-	-	-	-
	Profit/(Loss) for the Period	81.76	69.22	20.81	150.98	55.49	174.08
	Paid up Equity Share Capital	1,372.09	1,376.27	1,287.28	1,372.09	1,287.28	1,376.27
9	Earnings Per Share (EPS) (Not annualised)						
	(1) Basic	0.60	0.50	0.16	1.10	0.43	1.34
	(2) Diluted	0.60	0.50	0.16	1.10	0.43	1.34



NOTES

1. The above Financial Results which are published in accordance with Regulations 33 and Regulations 52 (4) read with regulation 63 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Friday, 31st October 2025
2. The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / reenactment(s) thereto). The Financial Results have been subjected to limited review by the Statutory Auditors of the Company, and they have expressed an unmodified review opinion.
3. The company has a single business segment, namely "Speciality Chemicals & Pharma Intermediates", therefore in the context of Ind AS 108, disclosure of segment information is not applicable.
4. Figures for the previous period have been regrouped/ reclassified wherever necessary to conform to current period's classification.

For Eiko LifeSciences Limited

Laxmikant Kabra
Chairman
DIN: 00061346



Date: 31st October 2025

Place: Thane



EIKO LIFESCIENCES LIMITED
(CIN: L65993MH1977PLC258134)

STANDALONE BALANCE SHEET FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2025

(INR in lakhs)

Particulars	As at 30-09-2025	As at 31-03-2025
ASSETS		
Non-current assets		
Property, Plant and Equipment	1,396.71	1,426.23
Financial Assets		
Investments	706.58	706.58
Loans and Advances	1,314.39	1,062.82
Other Financial Assets	200.00	-
	3,617.68	3,195.63
Current assets		
Inventories	209.87	401.63
Financial Assets		
Trade Receivables	1,296.97	1,013.65
Cash and cash equivalents	761.69	1,151.26
Other Current Assets	224.10	275.24
	2,492.63	2,841.78
TOTAL ASSET	6,110.31	6,037.41
EQUITY AND LIABILITIES		
EQUITY		
Equity Share capital	1,372.09	1,376.27
Other Equity	4,421.26	4,266.10
	5,793.35	5,642.37
LIABILITIES		
Non-current liabilities		
Financial Liabilities		
Non-Current Borrowings	-	99.89
Deferred Tax Liabilities	71.75	67.92
	71.75	167.81
Current liabilities		
Financial Liabilities		
Current Borrowings	-	75.51
Trade payables	161.01	110.79
Current Tax Liabilities	55.38	22.66
Provisions	26.81	1.01
Other current Liability	2.02	17.26
	245.22	227.24
TOTAL LIABILITIES	6,110.31	6,037.41






EIKO LIFESCIENCES LIMITED
(CIN: L65993MH1977PLC258134)

STANDALONE CASH FLOW STATEMENT FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2025

(INR in lakhs)

Particulars	Year ended 30-09-2025	Year ended 31-03-2025
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net (loss) / profit before tax	197.58	231.82
Adjustments for		
Depreciation and Amortisation Expense	29.51	62.94
Profit on sale of Investments	-	(1.45)
Finance Costs	8.79	12.70
Interest Income classified as investing cash flow	(104.93)	(90.90)
Exceptional Item classified as Financing cash flow	-	(34.12)
Operating profit before working capital changes	130.95	180.99
Working capital adjustments: -		
Increase / (Decrease) in Trade and Other Payables	50.22	(27.26)
Increase / (Decrease) in Provisions	25.80	(0.49)
Increase / (Decrease) in Other current Liabilities	(15.25)	12.81
Increase / (Decrease) in Current Borrowings	(75.51)	-
(Increase) / Decrease in Inventories	191.76	(63.07)
(Increase) / Decrease in Trade Receivables	(283.32)	299.72
(Increase) / Decrease in Other Current Assets	51.14	(168.90)
Cash generated from / (used in) operations	75.79	233.80
Direct taxes paid (Net of Refunds)	(10.04)	(29.20)
Net cash (used in) / from generated from operating activities	65.75	204.61
B. CASH FLOW FROM INVESTING ACTIVITIES		
Sale/(Purchase) of Investments	-	(303.36)
Sale/(Purchase) of Fixed Assets	-	(132.65)
Proceeds from Deposits, Loans and Advances	(451.57)	(640.12)
Interest Income	104.93	90.90
Net cash (used in) / generated from investing activities	(346.64)	(985.23)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of shares	-	434.58
Interest paid	(8.79)	(12.70)
Proceeds/(Repayment) from borrowings	(99.89)	175.40
Net cash (used in) / from financing activities	(108.68)	597.28
Net decrease in cash and cash equivalents (A+B+C)	(389.57)	(183.34)
Cash and cash equivalents at the beginning of the year	1,151.26	1,334.60
Cash and cash equivalents at the end of the year	761.69	1,151.26





P S V JAIN & ASSOCIATES

Office No. 105, Shree Yaswant shopping Centre, Kasturba Rd., No. 7,
Borivali (E), Mumbai - 400066. Tel. : +91-22-28059888 Mob.: 9920689888
E-mail : psvjain.associates@gmail.com

Independent Auditor's Review Report on Consolidated Unaudited Financial Results for Quarter and Half Year Ended 30th September 2025 of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

To the Board of Directors

Eiko LifeSciences Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results (the Statement') of Eiko LifeSciences Limited (the Holding Company') and its subsidiary (the Holding Company and its subsidiary together referred to as 'the Group') and its associate for the quarter and half year ended 30th September 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. The statement includes the results of following entity:

Parent	
1	Eiko LifeSciences Limited
Subsidiary	
2	Eiko Scientific Solutions LLP
3	Eikovivify Logistics Private Limited
Associate	
4	Reflux Pharmaceuticals Private Limited

4. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of people responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable



P S V JAIN & ASSOCIATES

Office No. 105, Shree Yaswant shopping Centre, Kasturba Rd., No. 7,
Borivali (E), Mumbai - 400066. Tel. : +91-22-28059888 Mob.: 9920688888
E-mail : psvjain.associates@gmail.com

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement
6. We did not review the interim financial results of associate included in the Statement whose interim financial information reflects total revenues of INR 945.97 lakhs and net profit after tax of INR 20.39 lakhs for the quarter and half year ended 30th September 2025 as considered in the Statement. These interim financial results have been reviewed by other auditors and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of associate is based solely on the reports of the other auditors and the procedures performed by us as stated above

Our conclusion on the Statement is not modified in respect of the above matter.

For PSV JAIN & ASSOCIATES

Chartered Accountants

Firm Registration No.: 131505W

CA Vijay Kumar Jain

Partner

Membership No.: 405129



Place: Thane

Date: 31st October 2025

UDIN: 25405129BMUJYV7161



EIKO LIFESCIENCES LIMITED
(CIN: L65993MH1977PLC258134)

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2025

(INR in Lakhs)

Sr. No.	Particulars	Quarter ended			Half Year Ended		Year ended
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	1,167.17	1,071.15	815.51	2,238.32	1,890.55	3,766.40
	Other income	26.10	26.52	13.07	52.62	39.29	71.61
	Total revenue	1,193.28	1,097.66	828.58	2,290.94	1,929.84	3,838.02
2	Expenses						
	Cost of material consumed	1,015.86	545.83	685.76	1,561.70	1,677.93	3,504.24
	Changes in inventories of finished stock and work-in-progress	(144.16)	284.31	34.10	140.15	33.94	(238.07)
	Employee benefits expense	13.74	12.56	6.71	26.29	12.02	36.66
	Depreciation and amortization expense	25.50	25.37	16.31	50.86	32.83	73.72
	Finance Cost	9.97	4.82	3.58	14.79	6.46	15.87
	Other expenses	105.24	77.34	46.88	182.58	85.28	187.55
	Total expenses	1,026.15	950.22	793.32	1,976.37	1,848.46	3,579.98
3	Profit before Exceptional Items, Share of Profit in Equity Accounted Investee and Tax	167.13	147.44	35.26	314.57	81.38	258.04
	Exceptional Items	-	-	-	-	4.82	34.12
4	Profit before Share of Profit in Equity Accounted Investee and Tax	167.13	147.44	35.26	314.57	86.20	292.16
	Share of profit/(loss) in equity accounted investees (net)	4.04	1.06	2.37	5.10	-	14.33
5	Profit before tax	171.17	148.50	37.63	319.67	86.20	306.49
6	Tax expense:						
	(1) Current tax	35.37	29.99	6.83	65.36	15.40	48.11
	(2) Deferred tax	7.33	6.78	2.64	14.11	5.52	26.52
7	Total Other Comprehensive Income (OCI)	-	-	-	-	-	-
8	Profit for the period	128.47	111.74	28.15	240.20	65.29	231.86
	Attributable to:		-	-	-	-	-
	(a) Shareholders of the company	107.56	91.42	28.15	198.98	65.29	210.57
	(b) Non- controlling interests	20.91	20.31	-	41.22	-	21.29
	Paid up Equity Share Capital	1,372.09	1,376.27	1,287.28	1,372.09	1,287.28	1,376.27
9	Earnings Per Share (EPS) (Not annualised)					-	
	(1) Basic	0.78	0.66	0.22	1.45	0.51	1.62
	(2) Diluted	0.78	0.66	0.22	1.45	0.51	1.62



NOTES

1. The above Financial Results which are published in accordance with Regulations 33 and Regulations 52 (4) read with regulation 63 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Friday, 31st October 2025.
2. The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to limited review by the Statutory Auditors of the Company, and they have expressed an unmodified review opinion.
3. Consolidated Financial Results include financial results of

Eiko Scientific Solutions LLP	Wholly Owned LLP
Eikovivify Logistics Private Limited	Subsidiary
Reflux Pharmaceuticals Private Limited	Associate Company
4. As per Ind AS 108 "Operating Segment" the Group has reported segment information mainly under two segments:
 - A. Speciality Chemicals & Pharma Intermediates
 - B. Logistics Services
5. Figures for the previous period have been regrouped/ reclassified wherever necessary to conform to current period's classification.

For Eiko LifeSciences Limited

L.K. Kabra

Laxmikant Kabra
Chairman
DIN: 00061346



Date: 31st October 2025

Place: Thane



EIKO LIFESCIENCES LIMITED
(CIN: L65993MH1977PLC258134)

CONSOLIDATED BALANCE SHEET FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2025

(INR in Lakhs)

Particulars	As at 30-09-2025	As at 31-03-2025
ASSETS		
Non-current assets		
Property, Plant and Equipment	2,261.04	2,311.91
Financial Assets		
Investments	720.50	715.40
Loans	455.44	295.15
Other Financial Assets	200.00	-
	3,636.99	3,322.46
Current assets		
Inventories	209.87	577.48
Financial Assets		
Trade Receivables	1,453.51	1,078.58
Cash and cash equivalents	808.69	1,178.06
Other Current Assets	366.90	453.56
	2,838.98	3,287.67
TOTAL ASSET	6,475.97	6,610.13
EQUITY AND LIABILITIES		
EQUITY		
Equity Share capital	1,372.09	1,376.27
Other Equity	4,505.75	4,302.58
Non-Controlling Interest	63.00	21.78
	5,940.84	5,700.64
LIABILITIES		
Non-current liabilities		
Financial Liabilities		
Non-Current Borrowings	100.90	200.83
Deferred Tax Liabilities	96.23	82.12
	197.13	282.95
Current liabilities		
Financial Liabilities		
Current Borrowings	-	75.51
Trade payables	171.87	331.47
Current Tax Liabilities	55.38	23.62
Provisions	60.05	16.76
Other current Liability	50.70	179.18
	337.99	626.54
TOTAL LIABILITIES	6,475.97	6,610.13





EIKO LIFESCIENCES LIMITED
(CIN: L65993MH1977PLC258134)

CONSOLIDATED CASH FLOW STATEMENT FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2025

(INR in Lakhs)

Particulars	Year ended 30-09-2025	Year ended 31-03-2025
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net (loss) / profit before tax	319.67	306.49
Adjustments for		
Depreciation and Amortisation Expense	50.86	73.72
Profit on sale of Investments	-	(1.45)
Profit on sale of Fixed Assets	-	(0.01)
Profit from Associate	(5.10)	-
Interest Income classified as investing cash flow	(52.58)	(69.29)
Interest Income classified as Financing cash flow	-	(34.12)
Finance Cost classified as financing cash flow	14.79	15.87
Operating profit before working capital changes	327.64	291.22
Working capital adjustments:		
Increase / (Decrease) in Trade and Other Payables	(159.60)	193.42
Increase / (Decrease) in Provisions	43.29	15.26
Increase / (Decrease) in Other current Liabilities	(128.48)	174.72
Increase / (Decrease) in current Borrowings	(75.51)	-
(Increase) / Decrease in Inventories	367.61	(238.91)
(Increase) / Decrease in Trade Receivables	(374.94)	234.80
(Increase) / Decrease in Other Current Assets	86.66	(347.22)
Cash generated from / (used in) operations	86.66	323.29
Direct taxes paid (Net of Refunds)	(33.60)	(30.92)
Net cash (used in) / from generated from operating activities	53.06	292.37
B. CASH FLOW FROM INVESTING ACTIVITIES		
Sale/(Purchase) of Investments	(0.00)	(312.19)
Sale/(Purchase) of Fixed Assets	-	(1,029.11)
Proceeds from Deposits, Loans and Advances	(360.29)	127.56
Interest Income	52.58	69.29
Net cash (used in) / generated from investing activities	(307.71)	(1,144.45)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of shares	-	434.58
Proceeds from issue shares of Non-Controlling Interest	-	0.49
Interest paid	(14.79)	(15.87)
Proceeds /(Repayment) from borrowings	(99.93)	276.34
Net cash (used in) / from financing activities	(114.72)	695.55
Net decrease in cash and cash equivalents (A+B+C)	(369.37)	(156.54)
Cash and cash equivalents at the beginning of the year	1,178.06	1,334.60
Cash and cash equivalents at the end of the year	808.69	1,178.06





SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES

The Group has identified two reportable business segments:

1. Speciality Chemicals & Pharma Intermediates
2. Logistics Services

The Logistics Services segment represents the core business of the Company's subsidiary, Eikovivify Logistics Private Limited, which commenced operations during the current financial year. Accordingly, segment-wise reporting has been provided for the quarter and half year ended 30th September 2025.

Sr. No.	Particulars	Quarter ended		Half Year Ended	Year Ended
		30-09-2025	30-06-2025	30-09-2025	31-03-2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
SEGMENT REVENUE					
a) Speciality Chemicals & Pharma Intermediates		1,025.24	840.22	1,865.46	3,357.93
b) Logistics Services		141.93	230.93	372.86	408.47
Total segment revenue		1,167.17	1,071.15	2,238.32	3,766.40
SEGMENT RESULTS					
a) Speciality Chemicals & Pharma Intermediates		72.15	44.42	116.57	133.55
b) Logistics Services		30.61	29.73	60.34	32.75
Total		102.76	74.15	176.91	166.30
Less: Finance Costs		-9.97	-4.82	-14.79	-15.87
Add: Other Income		48.97	50.62	99.58	93.51
Add: Share of Non-Controlling Interest		29.41	28.56	57.97	28.43
Add: Exceptional Items		-	-	-	34.12
Profit before tax		171.17	148.50	319.67	306.49
SEGMENT ASSETS					
a) Speciality Chemicals & Pharma Intermediates		3,722.81	3,781.52	3,722.81	3,874.75
b) Logistics Services		1,057.88	1,073.79	1,057.88	1,319.24
Total Segment Assets		4,780.70	4,855.31	4,780.70	5,194.00
Investments in equity accounted investees		920.23	716.19	920.23	715.13
Unallocated Assets		775.04	851.00	775.04	701.00
Total Assets		6,475.97	6,422.50	6,475.97	6,610.13
SEGMENT LIABILITIES					
a) Speciality Chemicals & Pharma Intermediates		353.47	435.79	353.47	398.03
b) Logistics Services		181.65	154.64	181.65	511.46
Total Segment Liabilities		535.13	590.43	535.13	909.49
Total Liabilities		535.13	590.43	535.13	909.49

